Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Lipidor AB (publ)
  6. Summary
    LIPI   SE0012558617

LIPIDOR AB (PUBL)

(LIPI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
9.5(c) 9.25(c) 9.44(c) 9.36(c) 9.07(c) Last
53 378 17 600 12 955 51 458 38 123 Volume
-2.76% -2.63% +2.05% -0.85% -3.10% Change
More quotes
Estimated financial data (e)
Sales 2021 15,5 M 1,69 M 1,69 M
Net income 2021 -17,9 M -1,96 M -1,96 M
Net Debt 2021 - - -
P/E ratio 2021 -15,1x
Yield 2021 -
Sales 2022 22,4 M 2,45 M 2,45 M
Net income 2022 -13,9 M -1,52 M -1,52 M
Net Debt 2022 - - -
P/E ratio 2022 -18,1x
Yield 2022 -
Capitalization 272 M 29,9 M 29,7 M
Capi. / Sales 2021 17,5x
Capi. / Sales 2022 12,1x
Nbr of Employees 1
Free-Float 45,1%
More Financials
Company
Lipidor AB is a Sweden-based drug delivery company focusing on topical medication. The Company is focused to develop, patent and commercialize formulation concepts and technologies based on lipids. The Company develops product concepts based on AKVANO technology, which represents a dosage form that creates a lipid layer on the skin surface for effective delivery of drugs and skin care treatment. The CompanyÔÇÖs... 
Sector
Pharmaceuticals
Calendar
02/21Earnings Release
More about the company
All news about LIPIDOR AB (PUBL)
11/25Lipidor publishes interim report for period 1 January - 30 September and Q3 2021
AQ
10/29Lipidor submits new patent application and expands collaboration with Cannassure using ..
AQ
10/29Lipidor AB Submits New Patent Application and Expands Collaboration with Cannassure The..
CI
10/19LIPIDOR : Warrant holders exercise all warrants in Lipidor's incentive program 2018/2021
AQ
09/27LIPIDOR : announces approval to start Phase III clinical study of drug candidate AKP02 for..
AQ
09/27Lipidor AB Announces Approval to Start Phase III Clinical Study of Drug Candidate Akp02..
CI
08/24LIPIDOR : publishes interim report for H1 2021
AQ
08/24Lipidor AB Announces Earnings Results for the Second Quarter and Six Months Ended June ..
CI
07/06LIPIDOR : Summer letter from Lipidor
AQ
07/01LIPIDOR AB : licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights..
AQ
07/01Lipidor AB Licence Agreement Grants RELIFE Srl, Exclusive Rights to Register, Promote, ..
CI
06/08LIPIDOR : Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)
AQ
06/08LIPIDOR : Bulletin from the annual general meeting of Lipidor AB (publ)
AQ
05/24LIPIDOR : NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (publ)
AQ
05/07LIPIDOR : NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)
AQ
More news
News in other languages on LIPIDOR AB (PUBL)

- No features available -

More news
Chart LIPIDOR AB (PUBL)
Duration : Period :
Lipidor AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LIPIDOR AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 9,07 SEK
Average target price 18,50 SEK
Spread / Average Target 104%
EPS Revisions
Managers and Directors
Ola Holmlund Chief Executive Officer
Michael Owens Chief Financial Officer
Karl Fredrik Sj÷vall Chairman
Jan Holmbńck Chief Scientific Officer
Gunilla Lundmark Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIPIDOR AB (PUBL)-32.77%30
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049